JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China flag China · Delayed Price · Currency is CNY
27.48
+0.04 (0.15%)
Feb 11, 2026, 4:00 PM EST

SHA:603235 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
2,1982,1811,8512,2532,4662,265
Other Revenue
282830.651.7155.9738.74
2,2262,2091,8822,3052,5222,304
Revenue Growth (YoY)
10.84%17.35%-18.34%-8.63%9.50%13.76%
Cost of Revenue
1,2481,2881,1741,4501,4321,054
Gross Profit
978.41920.91708.11854.671,0901,250
Selling, General & Admin
203.86177.02169.21174.88140.19130.02
Research & Development
102.43103.82111.9689.4658.9449.36
Other Operating Expenses
25.617.8619.8121.9722.7723.43
Operating Expenses
330.29301.92299.32282.46228.3201.83
Operating Income
648.13619408.79572.21862.111,048
Interest Expense
-5.17-2.48-2.1-6.93-12.67-13.06
Interest & Investment Income
43.2964.8176.5422.884.3413.2
Currency Exchange Gain (Loss)
54.1954.1931.2482.37-26.95-78.04
Other Non Operating Income (Expenses)
-29.58-1.250.32-1.74-1.61-0.94
EBT Excluding Unusual Items
710.86734.26514.79668.79825.22969.17
Gain (Loss) on Sale of Investments
2.72.24-4.33-6.61-
Gain (Loss) on Sale of Assets
-2.07-1.07-0.09-1.07-2.140.05
Asset Writedown
-9.38-0.61-0.19-0.86--3.29
Other Unusual Items
36.3236.9550.6654.5756.9180.8
Pretax Income
738.43771.77565.17725.76873.371,047
Income Tax Expense
121.39120.5589.32103.64129.49159.64
Net Income
617.04651.22475.85622.12743.89887.09
Net Income to Common
617.04651.22475.85622.12743.89887.09
Net Income Growth
10.69%36.85%-23.51%-16.37%-16.14%21.90%
Shares Outstanding (Basic)
435437437412394394
Shares Outstanding (Diluted)
435437437412394394
Shares Change (YoY)
-0.18%0.11%5.96%4.68%-0.10%-
EPS (Basic)
1.421.491.091.511.892.25
EPS (Diluted)
1.421.491.091.511.892.25
EPS Growth
10.89%36.70%-27.82%-20.11%-16.00%21.82%
Free Cash Flow
-235.15-567.3193.61346.11603.13860.63
Free Cash Flow Per Share
-0.54-1.300.440.841.532.18
Dividend Per Share
0.6800.6800.5000.710--
Dividend Growth
36.00%36.00%-29.58%---
Gross Margin
43.95%41.70%37.63%37.08%43.23%54.26%
Operating Margin
29.12%28.03%21.72%24.83%34.18%45.50%
Profit Margin
27.72%29.49%25.29%26.99%29.49%38.51%
Free Cash Flow Margin
-10.56%-25.69%10.29%15.02%23.91%37.36%
EBITDA
810.53770.02544.64695.81969.571,137
EBITDA Margin
36.41%34.87%28.94%30.19%38.44%49.37%
D&A For EBITDA
162.4151.02135.85123.6107.4689.33
EBIT
648.13619408.79572.21862.111,048
EBIT Margin
29.12%28.03%21.72%24.83%34.18%45.50%
Effective Tax Rate
16.44%15.62%15.80%14.28%14.83%15.25%
Revenue as Reported
2,2262,2091,8822,3052,522-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.